Intraocular Pressure Spikes after Aflibercept Intravitreal Injections
- PMID: 27409826
- DOI: 10.1159/000446878
Intraocular Pressure Spikes after Aflibercept Intravitreal Injections
Abstract
The objective of this study was to assess the intraocular pressure (IOP) as well as the anatomical modifications of the anterior segment following an aflibercept injection. Patients underwent an aflibercept intravitreal injection (IVI) (0.05 ml) with a 30.5-gauge needle and an antireflux system. IOP was assessed before injection (T0), immediately after (T1), and 5 min (T5), 15 min (T15), and 45 min (T45) after the IVI. Before the IVI and immediately after the T1 measurement, a PENTACAM® acquisition was used to evaluate the anterior chamber parameters (anterior chamber volume, depth and measure of the iridocorneal angle). At T0, IOP was 12.9 ± 1.3 mm Hg. IOP significantly increased after IVI (42.7 ± 3 mm Hg, p < 0.001). IOP returned to baseline at T45 (13.0 ± 1.2 mm Hg, p = 0.877). Anterior chamber volume decreased after IVI (160.6 vs. 168.3 mm3, p = 0.002). No significant changes were found for iridocorneal angle and anterior chamber depth. Aflibercept IVI causes an acute increase in IOP over a short period without iridocorneal angle closure.
© 2016 S. Karger AG, Basel.
Similar articles
-
Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study.Br J Ophthalmol. 2025 Apr 22;109(5):600-605. doi: 10.1136/bjo-2024-326053. Br J Ophthalmol. 2025. PMID: 39532510 Free PMC article.
-
New prefilled syringe aflibercept design. A cause of symptomatic IOP spike after aflibercept PFS?Rom J Ophthalmol. 2024 Jul-Sep;68(3):219-224. doi: 10.22336/rjo.2024.41. Rom J Ophthalmol. 2024. PMID: 39464766 Free PMC article.
-
Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy.Am J Ophthalmol. 2014 Aug;158(2):319-327.e2. doi: 10.1016/j.ajo.2014.04.029. Epub 2014 May 6. Am J Ophthalmol. 2014. PMID: 24814167 Clinical Trial.
-
Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy: Review of the Literature and Possible Role of Nitric Oxide.J Glaucoma. 2016 Mar;25(3):291-300. doi: 10.1097/IJG.0000000000000173. J Glaucoma. 2016. PMID: 25318578 Review.
-
[Ocular hypertension after intravitreal injections].Vestn Oftalmol. 2022;138(5. Vyp. 2):234-239. doi: 10.17116/oftalma2022138052234. Vestn Oftalmol. 2022. PMID: 36287161 Review. Russian.
Cited by
-
Effect of Estimated Individual Vitreous Volume on Intraocular Pressure Spikes after Intravitreal Anti-Vascular Endothelial Growth Factors Injection.Ophthalmic Res. 2025;68(1):108-116. doi: 10.1159/000543071. Epub 2024 Dec 18. Ophthalmic Res. 2025. PMID: 39694020 Free PMC article.
-
Background diseases and the number of previous intravitreal aflibercept injections on immediate intraocular pressure increase and vitreous reflux rate in phakic eyes.Int J Ophthalmol. 2024 Mar 18;17(3):545-550. doi: 10.18240/ijo.2024.03.17. eCollection 2024. Int J Ophthalmol. 2024. PMID: 38721500 Free PMC article.
-
Densitometric analysis of cornea in patients with neovascular age-related macular degeneration after intravitreal aflibercept loading dose.Ther Adv Ophthalmol. 2020 Aug 27;12:2515841420950857. doi: 10.1177/2515841420950857. eCollection 2020 Jan-Dec. Ther Adv Ophthalmol. 2020. PMID: 32923942 Free PMC article.
-
Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study.Br J Ophthalmol. 2025 Apr 22;109(5):600-605. doi: 10.1136/bjo-2024-326053. Br J Ophthalmol. 2025. PMID: 39532510 Free PMC article.
-
Contributing factors to short-term intraocular pressure elevation following intravitreal anti-VEGF injections.BMC Ophthalmol. 2025 May 7;25(1):281. doi: 10.1186/s12886-025-04111-x. BMC Ophthalmol. 2025. PMID: 40335957 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical